Abstract:
|
COVID-19 has presented numerous clinical trial challenges, including choice of appropriate endpoint in the absence of information, problems with monitoring caused by rapid enrollment, discerning whether subgroup effects are real, and timely release of information while ensuring robustness of results. I will discuss these issues in the context of the Adaptive COVID-19 Treatment Trials (ACTT) and in the planning of future trials for COVID-19.
|